Paysign (NASDAQ:PAYS) Given Outperform Rating at Barrington Research

Paysign (NASDAQ:PAYS)‘s stock had its “outperform” rating reiterated by Barrington Research in a report issued on Wednesday,Benzinga reports. They presently have a $7.00 price target on the stock. Barrington Research’s target price indicates a potential upside of 182.26% from the company’s previous close.

Separately, Lake Street Capital began coverage on shares of Paysign in a research note on Friday, December 20th. They issued a “buy” rating and a $6.00 target price on the stock.

Paysign Trading Down 1.6 %

Shares of Paysign stock opened at $2.48 on Wednesday. The firm has a fifty day simple moving average of $2.67 and a 200-day simple moving average of $3.25. The stock has a market capitalization of $132.80 million, a price-to-earnings ratio of 16.53 and a beta of 0.93. Paysign has a 1-year low of $2.25 and a 1-year high of $5.59.

Paysign (NASDAQ:PAYS) last announced its earnings results on Tuesday, March 25th. The company reported $0.02 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.02. Paysign had a net margin of 14.28% and a return on equity of 30.64%. As a group, research analysts predict that Paysign will post 0.21 earnings per share for the current year.

Insider Activity at Paysign

In other news, CEO Mark Newcomer sold 100,000 shares of the company’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $2.73, for a total value of $273,000.00. Following the completion of the transaction, the chief executive officer now owns 8,936,886 shares in the company, valued at $24,397,698.78. This represents a 1.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Topline Capital Management, Ll sold 231,187 shares of the firm’s stock in a transaction on Friday, December 27th. The stock was sold at an average price of $3.31, for a total transaction of $765,228.97. Following the sale, the insider now owns 5,859,046 shares in the company, valued at approximately $19,393,442.26. The trade was a 3.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 927,087 shares of company stock worth $2,872,039 in the last quarter. Corporate insiders own 23.40% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in PAYS. SG Americas Securities LLC grew its holdings in shares of Paysign by 33.5% in the 4th quarter. SG Americas Securities LLC now owns 15,508 shares of the company’s stock valued at $47,000 after acquiring an additional 3,895 shares in the last quarter. Sanctuary Advisors LLC boosted its position in Paysign by 4.3% during the third quarter. Sanctuary Advisors LLC now owns 121,089 shares of the company’s stock valued at $419,000 after purchasing an additional 5,000 shares during the last quarter. Barclays PLC grew its stake in Paysign by 10.8% in the fourth quarter. Barclays PLC now owns 52,178 shares of the company’s stock valued at $157,000 after purchasing an additional 5,088 shares in the last quarter. Wells Fargo & Company MN grew its stake in Paysign by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 15,385 shares of the company’s stock valued at $46,000 after purchasing an additional 5,243 shares in the last quarter. Finally, Rhumbline Advisers increased its position in shares of Paysign by 13.7% during the 4th quarter. Rhumbline Advisers now owns 44,284 shares of the company’s stock worth $134,000 after purchasing an additional 5,339 shares during the last quarter. Institutional investors and hedge funds own 25.89% of the company’s stock.

Paysign Company Profile

Paysign, Inc provides prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing services for businesses, consumers, and government institutions. Its product offerings include solutions for corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card.